Abstract:AIM:To measure in parallel the serum levels and the peripheral blood mononuclear cell (PBMC) mRNA expression of IL-1β, IL-6 and TNF-α both before and after exposure to risperidone during a 4-week treatment protocol for schizophrenia, and to determine whether the levels of these factors were correlated with clinical variables. METHODS: ELISA and reverse transcription-polymerase chain reaction (RT-PCR) techniques were applied to analyze serum levels and PBMC mRNA expression of IL-1β, IL-6 and TNF-α in 83 schizophrenia patients and 65 healthy control subjects. RESULTS: ① Serum IL-1β, IL-6 and TNF-α levels in the schizophrenia group both pre- and post-treatment with risperidone were significantly higher than those in the control subjects (P<0.05). Serum IL-1β levels of the schizophrenia patients decreased significantly after 4-week treatment (P<0.05). ② Serum TNF-α levels of the negative subtype patients were significantly higher than those of the positive subtype patients before treatment (P<0.05). Serum IL-1β of the schizophrenia group and TNF-α levels of the negative subtype patients decreased significantly after 4-week treatment (P<0.05). Serum IL-6 levels of the familial schizophrenia were significantly higher than those of the sporadic schizophrenia before treatment (P<0.05). Serum IL-1β levels of the schizophrenia group and serum TNF-α levels of the familial schizophrenia decreased significantly after 4-week treatment (P<0.05). ③ There was significant correlation between the levels of TNF-α and the severity of negative symptom clusters evaluated by the PANSS (r=0.412, P<0.05). There was significant correlation between the difference of serum IL-1β levels pre- and post- treatment and the rate of the decreased PANSS (r=0.368, P<0.05). ④ IL-1β, IL-6 and TNF-α mRNA expression in the PBMC from the schizophrenia group both pre- and post-treatment were significantly higher than those from the control subjects (P<0.05). IL-1β mRNA expression in the PBMC from the schizophrenia patients decreased significantly after 4-week treatment (P<0.05). CONCLUSION: ① Schizophrenia patients are in a state of immune activation. The difference of serum IL-1β level between pre- and post-treatment with neuroleptic may be a sensitive parameter of illness recovery. ② Changes in the immune system are involved in the pathophy-siology of schizophrenia. ③ PBMC of schizophrenia patient is activated and may be one of major sources of cytokines.

PANSS, MENTAL CONDITION AND INFLAMMATORY STATE OF RISPERIDONE ON SCHIZOPHRENIA

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

Study on Efficacy and Safety of Risperidone in Treatment of Different Kinds of Schizophrenia

Effect of Risperidone Monotherapy on Dynamic Functional Connectivity of Insular Subdivisions in Treatment-Naive, First-Episode Schizophrenia

Effect of risperidone treatment on insulin-like growth factor-1 and interleukin-17 in drug naïve first-episode schizophrenia

Serum protein and PBMC mRNA expressions of IL-1β, IL-6 and TNF-α in first-episode schizophrenia

Aripiprazole and risperidone in treatment of the patients with schizophrenia: a randomly clinical trial

Study on serum levels, PBMC mRNA expression of IL-1β in first-episode schizophrenics

Open Observation and Control Study of the Efficacy and Safety of Paliperi-done Extended-release Tablets and Risperidone Tablets in the Treatment of First-episode Schizophrenia

A clinical controlled study on schizophrenia treated with paliperidone-ER and risperidone

Relationship between plasma risperidone concentrations and clinical features in chronic schizophrenic patients in China

Double-blind Comparison of Ziprasidone and Risperidone in the Treatment of Chinese Patients with Acute Exacerbation of Schizophrenia

The neuroendocrine response to paroxetine challenge, immune indices, free radical metabolism and antipsychotic treatment in schizophrenia

Effect of Risperidone on Serum Homocysteine Levels in First-Episode, Drug-Naïve Patients with Schizophrenia.

Population Pharmacodynamic Models of Risperidone on PANSS Total Scores and Prolactin Levels in Schizophrenia

Observation of Ziprasidone and risperidone in the treatment of female patients with schizophrenia

A Control Study on Aripiprazole and Risperidone in the Treatment of Schizophrenia.

Effect of resperidone treatment on serum levels of nonenzymatic antioxidant in drug-na?ve first-episode schizophrenic patients

Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia

THERAPEUTIC AND ADVERSE EFFECTS OF RISPERIDONE IN TREATMENT OF DIFFERENT GENDER PATIENTS WITH SCHIZOPHRENIA